US-Trained Uyghur Scientist Found Detained After His WeChat Went Silent

A Uyghur research scientist at a Chinese university in Shanghai who suddenly went silent in April after an active presence on social media has been confirmed detained, the latest of many intellectuals from Xinjiang to disappear from public life into internment camps or prisons.

Tursunjan Nurmamat, who had lived in the United States between 2009 and 2018 and earned doctorate from the University of Wyoming, has been in police custody for three months, according to sources at Tongji University, where he had worked since July 2018.

An official at Tongji University in Shanghai confirmed that Tursunjan is in custody and under police investigation.

“This is currently in the process of investigation,” he said. “We know basic details, but nothing else. The Public Security Bureau is not talking with us,” the official said.

When RFA asked for the name of the Uyghur instructor detained from the school, a second university staff member mentioned Tursunjan, who was born in 1985 in Yarkand (in Chinese, Shache) county in Kashgar in the far west of the Xinjiang Uyghur Autonomous Region (XUAR).

Tursunjan, who did postdoctoral research in Texas and California, is the latest in a growing number of Uyghur intellectual, cultural, and religious thought leaders to be incarcerated in the XUAR in what experts say is a larger Chinese effort to erase Muslim and Uyghur culture and force the 12 million Uyghurs to assimilate.

The jailing of Uyghur cultural leaders, which has gotten increasingly heavy-handed since 2016, is part of a set of policies has been deemed by the U.S. and others as constituting genocide that also includes forced labor at factories and farms, forced birth control, and the detention of up to 1.8 million Uyghurs in a network of internment camps.

Abduweli Ayup, founder of Uyghur Hjelp, a Norway-based Uyghur advocacy and aid organization which maintains a list of detained Uyghur intellectuals, wrote on Twitter in June that Tursunjan had disappeared from Chinese social media two months earlier.

Abduweli told RFA he tried to investigate, but could not obtain much information on the academic, who he said focused on his studies in molecular and cellular life science in his work and avoided involvement in political activities while he was in the U.S.

Tursunjan, who also goes by the pen name Bilge, started a job at Tongji University in July 2018 and continued to post regularly online until he stopped doing so in early April, said Abduweli.

Among Tursunjan’s last posts to his WeChat account was a photo of his mother, wife, and daughter celebrating International Women’s Day on March 8.

During the first week of April, he also posted on WeChat that he was happy to have been transferred to a new job at Cell Research, a Chinese monthly peer-reviewed scientific journal covering cell biology.

But soon after Tursunjan announced that he had begun working at Cell Research, his name disappeared from the publication’s website.

“At that point we began to worry that Tursunjan had been detained,” Abduweli said.

“We spread the news on social media, and then, after looking into Tursunjan’s situation, we were able to obtain a bit of information about it. Ultimately, we are concerned about what has happened to Tursunjan,” said Abduweli.

Abduweli and several of Tursunjan’s friends in the U.S. wrote to the publishers of Cell Research and received a response that the journal was unable to provide personal information about its editors.

RFA sent an email to the journal on July 17 asking for information about Tursunjan but has not yet received a response.

Reported by Shohret Hoshur for RFA’s Uyghur Service. Translated by the Uyghur Service. Written in English by Roseanne Gerin.

Chinese Billionaire Who Helped Rights Lawyers Describes ‘Inhumane’ Detention

Agriculture billionaire Sun Dawu, who is currently standing trial in the northern Chinese province of Hebei on a slew of charges that rights activists say are politically motivated, was subjected to “cruel and inhumane treatment,” his defense team said.

Sun, 67, is on trial at the Gaobeidian Municipal People’s Court amid unprecedented security that lawyers said is tantamount to a secret trial.

The Chinese Human Rights Defenders (CHRD) network said he is being targeted for political reasons, due to his association with detained democracy activist Xu Zhiyong.

Following his detention April 2021 alongside dozens of Dawu Agricultural and Animal Husbandry Group employees, some of whom are members of his family, Sun and six others were held incommunicado under “residential surveillance at a designated location (RSDL).”

He told the court that he had requested a transfer to a regular detention center because of the way he was treated under RSDL.

“During RSDL, I once requested to be transferred to the detention center because my treatment produced misery beyond words and life was worse than death,” Sun told the court on July 16, in comments translated by his defense team.

“I went on a hunger strike for three days,” he said. “[Eventually] they gave me an hour of yard time. I saw the sun for the first time in three and a half months.”

Sun was detained in April 2021 alongside dozens of Dawu Agricultural and Animal Husbandry Group employees, some of whom are members of his family, after Dawu employees in August 2020 tried to stop a state-owned enterprise from demolishing a company building.

Seven of the defendants were placed under RSDL, and also reported being subjected to cruel and inhuman treatment, the defense team statement said.

Family also mistreated

Sun’s brother Sun Sanwu said he had lost around 26 pounds in weight during his time in RSDL.

“The treatment we received under RSDL was inhuman,” he told the court. “I signed whatever they asked me to sign. I only begged them to send me to the detention center as soon as possible.”

“First, they made me confess, and then they put a hood over my head and took me to the law enforcement investigation center to synchronize my speech,” he said.

Sun, a former pig farmer, stands accused of a slew of offenses, including “picking quarrels and stirring up trouble,” “gathering a crowd to attack an organ of the state,” “disrupting official duties,” “illegal mining,” and “illegal occupation of agricultural land.”

His son Sun Fushuo also reported mistreatment during interrogation: “I was handcuffed to the interrogation chair for 30 hours until my legs were swollen. They said that if I refused to cooperate, they would place me under RSDL,” he told the court.

“They all knew what they were doing. The police interrogators made it clear: Don’t think we can’t make you submit; we can place you under RSDL. I knew that RSDL was terrible, and I was scared,” he said.

“The subsequent interrogation transcripts were made under such duress.”

Sun Dawu’s former assistant Ji Weilian is “extremely weak and on the verge of a mental breakdown” since going into RSDL, the defense team’s statement said.

Dawu Group legal direct Yang Bin said the trial was effectively being held behind closed doors, with only one family member allowed into the court per defendant.

“There is a high-level of stability maintenance measures in place,” Yang said.

Several members of Sun Dawu’s defense team turned down requests for interviews when contacted by RFA in recent days, saying it was “inconvenient,” a phrase often used to indicate pressure from the authorities.

Translated and edited by Luisetta Mudie.

WillScot Mobile Mini Holdings to Announce Second Quarter 2021 Results on August 5, 2021

PHOENIX, July 20, 2021 (GLOBE NEWSWIRE) — WillScot Mobile Mini Holdings Corporation (Nasdaq: WSC) today announced that it will release its second quarter 2021 financial results on Thursday, August 5, 2021 after the markets close.

Chief Executive Officer, Brad Soultz and Chief Financial Officer, Tim Boswell will host a conference call and webcast on Friday, August 6, 2021 at 10:00 a.m. EDT to discuss the results.

The live call can be accessed by dialing (855) 312-9420 (US/Canada toll-free) or (210) 874-7774 (International). A live webcast will also be accessible via the “Events & Presentations” section of the company’s website www.willscotmobilemini.com. An archived version of the webcast will be available for 60 days following the call.

About WillScot Mobile Mini Holdings

WillScot Mobile Mini Holdings trades on the Nasdaq stock exchange under the ticker symbol “WSC.” Headquartered in Phoenix, Arizona, the Company is a leading business services provider specializing in innovative flexible workspace and portable storage solutions. WillScot Mobile Mini services diverse end markets across all sectors of the economy from a network of approximately 275 branch locations and additional drop lots throughout the United States, Canada, Mexico, and the United Kingdom.

Additional Information and Where to Find It

Additional information can be found on the company’s website at www.willscotmobilemini.com

Contact Information

Investor Inquiries:

Nick Girardi
nick.girardi@willscotmobilemini.com

Media Inquiries:

Scott Junk
scott.junk@willscotmobilemini.com

Eyenuk Announces $6.2 Million Financing to Accelerate Adoption of FDA-cleared AI Technology for Detection of Diabetic Retinopathy

Financing led by AXA IM’s Impact Investing strategy

LOS ANGELES, July 20, 2021 (GLOBE NEWSWIRE) — Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening, today announced that it has completed a financing round of US$6.2 million led by AXA IM, through AXA IM Alts, a global leader in alternative investments with c. €162 billion of assets under management1. Eyenuk’s existing investors also participated in the round.

Eyenuk will use the proceeds to immediately accelerate commercialization of the EyeArt® AI System, which received FDA clearance in 2020 and is being reimbursed by Medicare and other payors.

AXA IM Alts’ investment in Eyenuk is advised by Dr. Zina Affas Besse, Managing Partner at Global Health Investment Advisors (GHIA), a pioneer in impact investing in life science companies. “We are very impressed with all that the Eyenuk team has accomplished to date,” said Dr. Affas Besse. “We look forward to supporting the company as it accelerates global commercialization and pipeline development programs.”

“We are excited about Eyenuk’s business potential as evidenced by Eyenuk’s impressive business and clinical accomplishments to-date,” said Jonathan Dean, Head of Impact Investing at AXA IM Alts. “We are proud to invest in some of the most innovative technologies that address major public health issues worldwide, while searching to generate attractive social and financial returns. Eyenuk’s innovative healthcare AI technologies aim to deliver tangible impact around the world alongside attractive financial returns.”

“We are thrilled to welcome new institutional investors to the Eyenuk team,” said Kaushal Solanki, Ph.D., Founder and CEO of Eyenuk. “We look forward to working with AXA IM Alts and other investors, who share Eyenuk’s vision of creating globally-accessible AI platform technology that can enable drastic reduction of preventable blindness across the world.”

Eyenuk plans to close a larger round of financing in late 2021 to support its long-term growth and innovation strategies.

About the EyeArt AI System
The EyeArt AI System provides fully automated DR screening, including retinal imaging, DR detection based on international clinical standards and immediate reporting, in a single office visit during a diabetic patient’s regular exam. Once the patient’s fundus images have been captured and submitted to the EyeArt AI System, the DR detection results are available in a PDF report in less than 30 seconds.

The EyeArt AI System was developed with funding from the U.S. National Institutes of Health (NIH) and is validated by the U.K. National Health Service (NHS). In addition to US FDA 510(k) clearance, the EyeArt AI System has CE marking as a class 2a medical device in the European Union and a Health Canada license. It is designed to be General Data Protection Regulation (GDPR) and Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.

EyeArt is reimbursed by government and private payors in the U.S. under the newly created Current Procedural Terminology (CPT) code 92229. Medicare started its national coverage for CPT 92229 on January 1, 2021.

VIDEO: Learn more about the EyeArt AI System for Autonomous Detection of Diabetic Retinopathy

About Eyenuk, Inc.
Eyenuk, Inc. is a global artificial intelligence (AI) medical technology and services company and the leader in real-world AI Eye Screening for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance. Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk and Alzheimer’s disease. Find Eyenuk online on its website, Twitter, Facebook, and LinkedIn.

About AXA IM’s approach to impact investing
AXA IM manages a variety of impact strategies, ranging from private equity investments to green and social bonds and listed equities and bonds, which look to provide solutions relating to issues such as healthcare, climate change and biodiversity.

AXA IM’s impact range is its most focused responsible investment offering, with products specifically designed to have a direct, measurable and positive impact on society and/or the environment. These strategies will report definitive and measurable data against impact KPIs such as carbon footprint or lives improved, and each will target one or more UN SDGs. These strategies have a parallel commitment to deliver returns by tapping into the key themes of the sustainability economy. As of the end of March 2021, AXA IM managed about €2.6 billion of assets in this category. More information about AXA IM’s approach to impact investing here.

About AXA IM Alts 
AXA IM Alts is a global leader in alternative investments with €162 billion of assets under management1 as of 31 March 2021, across real assets (real estate & infrastructure), private debt & alternative credit and private equity & hedge funds. AXA IM Alts employs over 750 people located in 16 offices around the world and serves the needs of more than 350 clients from Europe, North America, Asia Pacific and Middle East. We are a global leader in real assets investment with c. €109 billion of assets under management, the number one property portfolio and asset manager in Europe2, and one of the largest worldwide.

Visit our websites https://realassets.axa-im.com and www.axa-im.com. Follow us on Twitter @AXAIMRealAssets and @AXAIM.

About Global Health Investment Advisors
Through its work as the investment manager for the Global Health Investment Fund and its partnership with AXA IM Alts, Global Health Investment Advisors has pioneered impact investing in life science companies. The firm seeks attractive financial returns and works with companies to facilitate the introduction of innovative products worldwide, including low-income countries. Its portfolio companies have generated compelling exits and have saved and improved millions of lives. Find GHIA online on its website.

Eyenuk, Inc. Contact
Frank Cheng, President & CCO
frank.cheng@eyenuk.com
+1 818 835 3585

1 Source: AXA IM Alts unaudited data, as of March 2021.
2 Source: INREV Fund Manager Survey, June 2021. #1 largest European managers in total real estate assets under management.

Blue California Commercializes Nicotinamide Mononucleotide (NMN) for Supporting an Increased Healthspan

A better cost-effective option is now available for dietary supplement, functional food, and beverage manufacturers.

Rancho Santa Margarita, Calif., July 20, 2021 (GLOBE NEWSWIRE) — Blue California joins with the innovative Massachusetts-based biotech company Conagen to announce the commercialization of high-purity, fermentation-derived nicotinamide mononucleotide (NMN). A nature-based metabolic component which has caught the attention of health-conscious consumers for supporting energy and longevity.

The quest to age healthily and support longevity is surging among health-conscious consumers. “Consumers are reassessing their dietary regimen to make room for ingredients that can support an increased healthspan,” said Chief Science Officer at Blue California, Dr. Priscilla Samuel.

NMN supplements are highly sought-after for healthy aging applications, including brain health, vitality, heart health, metabolic health, and even cosmetics. However, current NMN ingredients used in products on the market are mostly produced by chemical synthesis.

While consumers are exploring dietary supplements for a holistic approach to health, they are also demanding clean labels from their supplements, and moving away from synthetic ingredients. Blue California’s fermentation-derived NMN opens new opportunities for producers to consider consumers’ health more holistically while acquiring a closer-to-nature position.

NMN serves as a precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme present in all living cells and critical for mitochondrial function.

Increased intracellular levels of NAD+ boost energy production and improve cellular health, but levels decline dramatically with age. Replenishing NAD+ in the body with its precursor NMN has been proposed as a way to possibly combat age-related degeneration and increase healthy lifespan.

“Our fermentation-derived offering is well-positioned to capitalize on the growing recognition of NMN as an important ingredient in the food and supplement spaces,” said Samuel. “NMN is a well-known molecule in the longevity research community, and emerging research also suggests potential applications for immune health as well as sports nutrition.”

Harvard professor David Sinclair, a well-recognized leader in the field of aging research, is an advocate of NMN for improving the health of aging populations.

“NMN is a logical extension to our line of “longevity ingredients” which includes ergothioneine and pyrroloquinoline quinone. All of these molecules are made by our own proprietary fermentation processes, enabling our customers to better serve consumers who might reject chemically-derived ingredients,” said VP of Innovation at Conagen, Dr. Casey Lippmeier. “Because of the way we make it, Conagen’s NMN is of the highest purity and quality.  It is also very cost-effective and compatible with clean-label trends, all of which demonstrates our strength as a strategic partner with Blue California.”

As innovation in dietary supplemental nutrition advances, so does the growth of global vitamin, mineral and supplement (VMS) launches. Mintel reported a growth of 67% of global VMS launches in Apr 2020 – Mar 2021, as compared to Apr 2016 – Mar 2017 — where the United States leads the VMS market.

About Blue California

Blue California is a vertically integrated technology company providing innovative ingredient solutions to global partners. With more than 20 years of innovation success, our ingredients are used in commercial products and applications in the industries of nutrition, personal care, healthy aging and wellness, functional food and beverage, and beauty. www.bluecal-ingredients.com

About Conagen

Conagen is making the impossible possible. Our scientists and engineers use the latest synthetic biology tools to develop high-quality sustainable nature-based products through systems of manufacturing on a molecular level and fermentation basis. We focus on the bioproduction of high-value ingredients for food, nutrition, flavors and fragrances, pharmaceutical, and renewable materials industries. www.conagen.com

Attachment

Ana Arakelian
Blue California ingredients
+1-949-635-1991
ana@bluecal-ingredients.com

Halfords Implements Descartes’ Last Mile Delivery Solution to Enable Dynamic Delivery Appointment Pricing in Mobile Service Business and as Part of New Avayler Field Service Software Platform

LONDON, July 20, 2021 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, has announced that UK-headquartered Halfords, a leading automotive products and services retailer, is using Descartes’ last mile delivery solution to enable dynamic delivery pricing in its customer-facing mobile tire replacement service and as its new international field service software solution called Avayler. First metrics show that Halford’s mobile service business has already been able to improve gross profit by 5% and reduce miles per delivery by 13%.

Descartes’ last mile delivery solution provides an end-to-end platform for home and last mile delivery operations. The solution spans delivery appointment booking, route planning and execution, mobile proof-of-delivery (POD) and notifications processes. Its delivery appointment schedule is dynamically generated for each customer and time window options are scored. This allows organizations such as Halfords to intelligently control the booking process, which maximizes booking density and productivity and enhances the customer experience while minimizing costs.

“As part of our innovative ecommerce-based mobile tire replacement service, we wanted to more accurately reflect the logistics cost of the mobile service when customers were booking service appointments and balance demand with our ability to serve customers,” said Chris McShane, Director, Strategy, Transformation & Business Development at Halfords. “Extending Descartes’ dynamic scheduling solution into Avayler made perfect sense. The solution will allow garages, distributors and other service-based organizations to provide their customer base with unique service appointment pricing as they are making purchases and the ability to optimize customer demand.”

The advanced real-time capabilities of the Descartes solution enable Halfords to offer dynamic delivery pricing that considers existing orders, business objectives, road network, vehicle capacity and service constraints to price delivery appointment options. In addition, Halfords uses Descartes’ forward-looking vehicle capacity information to help adjust its online marketing to ensure it balances demand generation with the ability to service that demand. As a result, Halfords has been able to target pay-per-click marketing spend by matching orders booked with the ability to service more customers in the coming days in particular regions.

After successfully using the Descartes last mile delivery solution to drive efficiencies in its own operations, Halfords has now integrated it into Avayler, its newly launched, end-to-end, customer-centric field service solution that will be rolled out globally. Avayler will provide other businesses with an end-to-end SaaS solution wherever they offer services whether in store, at garages, workshops, clinics, pop-up sites, in the driveway or across the threshold.

“By using logistics information and constraints in real-time during the customer buying experience, Halfords is taking last mile delivery strategies and solutions the next level,” said Pol Sweeney, Vice President of U.K. and Ireland Sales at Descartes. “Home and last mile delivery and services continue to be market differentiators, but expensive to operate. Halfords’ combination of our dynamic delivery appointment booking with its advanced pricing algorithms and capacity management allow the company to provide one of the most innovative and intuitive field service solutions on the market.”

About Halfords
Halfords is the U.K.’s leading retailer of motoring and cycling products and services. Through Halfords Autocentres, it is also one of the U.K.’s leading independent operators in vehicle servicing, maintenance and repairs. Headquartered in Redditch, West Midlands, Halfords employs nearly 10,000 colleagues up and down the country. For more information, visit www.halfords.com or contact:

Steve Marinker – +44 (0)7779 031 936
steve.marinker@powerscourt-group.com

Harold Amoo – +44 (0)7864 607 220
harold.amoo@powerscourt-group.com

About Descartes
Descartes (Nasdaq:DSGX) (TSX:DSG) is the global leader in providing on-demand, software-as-a-service solutions focused on improving the productivity, performance and security of logistics-intensive businesses. Customers use our modular, software-as-a-service solutions to route, schedule, track and measure delivery resources; plan, allocate and execute shipments; rate, audit and pay transportation invoices; access global trade data; file customs and security documents for imports and exports; and complete numerous other logistics processes by participating in the world’s largest, collaborative multimodal logistics community. Our headquarters are in Waterloo, Ontario, Canada and we have offices and partners around the world. Learn more at www.descartes.com, and connect with us on LinkedIn and Twitter.

Global Media Contact
Cara Strohack
Tel: +1(800) 419-8495 ext. 202025
cstrohack@descartes.com

Cautionary Statement Regarding Forward-Looking Statements
This release contains forward-looking information within the meaning of applicable securities laws (“forward-looking statements”) that relate to Descartes’ solution offering and potential benefits derived therefrom including the ability to combine certain capabilities of Descartes with the proprietary systems of Halfords; and other matters. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to differ materially from the anticipated results, performance or achievements or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the factors and assumptions discussed in the section entitled, “Certain Factors That May Affect Future Results” in documents filed with the Securities and Exchange Commission, the Ontario Securities Commission and other securities commissions across Canada including Descartes most recently filed management’s discussion and analysis. If any such risks actually occur, they could materially adversely affect our business, financial condition or results of operations. In that case, the trading price of our common shares could decline, perhaps materially. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Forward-looking statements are provided for the purposes of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. We do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.